Back to School: How biopharma can reboot drug development. Access exclusive analysis here
KOSN said that 340 mg/m 2 of its tanespimycin produced lower response rates than those seen in an earlier group given
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury